Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance

NCT02928614 · Completed

Last updated 2026-05-28

This clinical trial is testing biomarkers in overweight or obese adults with knee osteoarthritis to see how weight maintenance affects a specific protein linked to joint breakdown.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18–74 · all sexes

Timeline Started 2016-11 · est. completion 2019-03

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02928614 ↗

Description as written by the study sponsor.

This is a substudy to a randomized trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which they will be randomized to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. This substudy aims to investigate the impact of, and subsequent change of biomarkers in obese patients with knee osteoarthritis following a randomization to Liraglutide 3 mg or Liraglutide 3 mg placebo treatment between weeks 0-52.

Treatments tested

Liraglutide 3 mg (Saxenda) Drug
Liraglutide 3 mg placebo Drug

Main thing measured	Change in collagen II degradation fragment α-C2M
Sponsor	Henrik Gudbergsen
Conditions studied	Osteoarthritis, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02928614 ↗